Alpha Tau Medical Ltd. (DRTS)
NASDAQ: DRTS · Real-Time Price · USD
3.100
-0.020 (-0.64%)
Dec 20, 2024, 4:00 PM EST - Market closed
Alpha Tau Medical Employees
Alpha Tau Medical had 121 employees as of December 31, 2023. The number of employees increased by 27 or 28.72% compared to the previous year.
Employees
121
Change (1Y)
27
Growth (1Y)
28.72%
Revenue / Employee
n/a
Profits / Employee
-$244,950
Market Cap
216.76M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 121 | 27 | 28.72% |
Dec 31, 2022 | 94 | 11 | 13.25% |
Dec 31, 2021 | 83 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Aurora Cannabis | 1,073 |
BGM Group | 298 |
Precigen | 202 |
Nautilus Biotechnology | 167 |
Profound Medical | 131 |
Mersana Therapeutics | 123 |
Fulcrum Therapeutics | 76 |
Ocugen | 65 |
DRTS News
- 3 days ago - Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day - GlobeNewsWire
- 4 days ago - Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor - GlobeNewsWire
- 10 days ago - Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 15 days ago - Alpha Tau to Participate in Ladenburg's Oncology Innovators & Investors Symposium - GlobeNewsWire
- 5 weeks ago - Alpha Tau to Participate in Citi's 2024 Global Healthcare Conference and Piper Sandler's 36th Annual Healthcare Conference - GlobeNewsWire
- 2 months ago - Alpha Tau Announces Acceptance Into FDA's Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme - GlobeNewsWire
- 2 months ago - Alpha Tau Treats First Patient with Recurrent Lung Cancer - GlobeNewsWire
- 3 months ago - Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC - GlobeNewsWire